A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.
Key Inclusion Criteria:
Key Exclusion Criteria:
New York, New York 10016, United States
Nishinomiya-shi, HyogoKen, Japan
Ube-shi, Yamaguchi 755-8505, Japan
Kazan', 420021, Russia
Novosibirsk, 630068, Russia